Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.3M | $91.7M | $63.2M | $322M | $24.0M | $298K | $139K | $1.20M | $31.1M | $49.8M |
| Revenue growth | — | 15.7% | -31.1% | 409.5% | -92.5% | -98.8% | -53.4% | 766.2% | 2481.5% | 60.2% |
| Operating income | -$127M | -$131M | -$103M | $141M | -$47.8M | -$87.1M | -$101M | -$172M | -$197M | -$48.9M |
| Operating margin | -160.5% | -142.5% | -163.4% | 43.9% | -199.2% | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Net income | -$131M | -$123M | -$121M | $130M | -$58.6M | -$87.8M | -$102M | -$177M | -$200M | -$50.3M |
| Net margin | -165.8% | -134.1% | -190.7% | 40.4% | -244.1% | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (diluted) | -$1.27 | -$1.17 | -$1.14 | $1.16 | -$0.53 | -$0.60 | -$0.62 | -$0.80 | -$0.63 | -$0.14 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$176M | -$185M | -$149M | $114M | -$143M | -$87.0M | -$88.9M | -$162M | -$179M | -$67.9M |
| Capital expenditures | $231K | $228K | $95.0K | $70.0K | $87.0K | $1.22M | $1.33M | $470K | $1.03M | $0.00 |
| Free cash flow | -$176M | -$186M | -$149M | $114M | -$143M | -$88.2M | -$90.2M | -$162M | -$180M | -$67.9M |
| Share buybacks | $621K | $1.68M | $972K | $941K | $1.03M | $2.67M | $864K | $824K | $1.73M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $46.6M | $61.7M | $80.4M | $36.1M | $126M | $64.1M | $46.3M | $22.5M | $66.7M | $34.3M |
| Total assets | $476M | $437M | $284M | $418M | $204M | $137M | $194M | $229M | $298M | $185M |
| Total liabilities | $318M | $368M | $311M | $301M | $47.4M | $23.3M | $77.2M | $136M | $152M | $77.4M |
| Long-term debt | $85.2M | $232M | $244M | $234M | $0.00 | $0.00 | $48.6M | $99.5M | $100M | $49.4M |
| Shareholders' equity | $168M | $68.3M | -$26.4M | $117M | $156M | $114M | $117M | $93.1M | $146M | $108M |
| Retained earnings | -$1.25B | -$1.37B | -$1.47B | -$1.34B | -$1.40B | -$1.49B | -$1.59B | -$1.77B | -$1.97B | -$2.02B |
| Shares (wtd avg diluted) | — | 105M | 106M | 117M | 111M | 146M | 166M | 221M | 320M | 363M |
Every figure is extracted from LEXICON PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.